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Abstract
Background: Despite ethnic disparities in lipid profiles, there are few genome-wide association studies
investigating genetic variation of lipids in non-European ancestry populations. In this study, we present findings
from genetic association analyses for total cholesterol, low density lipoprotein cholesterol (LDL), high density
lipoprotein cholesterol (HDL), and triglycerides in a large Hispanic/Latino cohort in the U.S., the Hispanic
Community Health Study / Study of Latinos (HCHS/SOL).
Methods: We estimated a heritability of approximately 20% for each lipid trait, similar to previous estimates in
Europeans. To search for novel lipid loci, we performed conditional association analysis in which the statistical
model was adjusted for previously reported SNPs associated with any of the four lipid traits. SNPs that remained
genome-wide significant (P < 5 × 10−8) after conditioning on known loci were evaluated for replication.
Results: We identified eight potentially novel lipid signals with minor allele frequencies <1%, none of which
replicated. We tested previously reported SNP-trait associations for generalization to Hispanics/Latinos via a
statistical framework. The generalization analysis revealed that approximately 50% of previously established lipid
variants generalize to HCHS/SOL based on directional FDR r-value < 0.05. Some failures to generalize were due to
lack of power.
Conclusions: These results demonstrate that many loci associated with lipid levels are shared across populations.
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Background
Lipid level profiles are important determinants of heart
and vascular health [1], with a disproportionate preva-
lence of unhealthy lipid profiles among U.S. minority
populations, especially Hispanics/Latinos [2, 3]. The
most commonly studied lipid traits include total choles-
terol, high-density lipoprotein cholesterol (HDL), low-
density lipoprotein cholesterol (LDL), and triglycerides.
High levels of LDL and triglycerides are considered risk
factors for coronary heart disease (CHD) while the op-
posite is true for HDL levels [4] .
The estimated heritability of lipid traits from twin and
family studies, generally studied in European descent
populations, ranges from 20% to higher than 70% [5].
The largest genome-wide association study (GWAS) re-
ported to date identified 157 common genetic variants
(minor allele frequency [MAF] > 2%) in over 188,000
participants from European-descent populations [6, 7]
and several of the loci marked by these variants also
have secondary signals, defined as associations that
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remain (or become) statistically significant after condi-
tioning on the most significant SNP in the region [8].
Collectively, these common variants explain ~30-33% of
the phenotypic variance for these traits in samples of
primarily European ancestry [8].
Despite the disparities surrounding unhealthy lipid
profiles [2, 3], there is a dearth of genetic studies investi-
gating lipids in non-European populations. While most
lipid-associated loci were discovered in studies of Euro-
peans, a few studies of lipids have identified population-
specific signals in African, Asian, and Hispanic/Latino
descent populations [9–15]. Previous studies [14] show
that by studying multiple ethnicities one can leverage
differences in associations, allele frequencies, and linkage
disequilibrium (LD) patterns to fine-map known loci
and narrow down the region in which functional vari-
ants are expected. Therefore, studies in diverse ethnici-
ties are important to increase understanding of the
differences in lipid profiles across populations, to ascer-
tain whether these differences are due to genetic archi-
tecture, and finally, for fine-mapping of known loci.
In this study, we present findings from a large His-
panic/Latino cohort, the Hispanic Community Health
Study / Study of Latinos (HCHS/SOL). We tested the
association of more than 25 million genotyped or im-
puted variants with four lipid traits: LDL, HDL, total
cholesterol, and triglycerides. Further, we sought to iden-
tify new signals within known association regions by
implementing statistical models conditioned on previ-
ously reported associated SNPs [9, 11–14]. We assessed
SNP associations that were significant in the conditional
model for replication in a Hispanic/Latino meta-analysis,
and for generalization in European- and African-descent
study populations. In addition, we assessed the pheno-
typic variance in lipid traits explained by common SNPs
across the genome in the HCHS/SOL.
Methods
Participants and study design
The HCHS/SOL is a community-based cohort study of
16,415 self-identified Hispanic/Latino individuals aged
18 - 74 from randomly selected households near four
U.S. field sites (Chicago, IL; Miami, FL; Bronx, NY; and
San Diego, CA) [16]. The two-stage probability sample
design was previously described in LaVange et al. [17].
HCHS/SOL cohort includes participants who self-
identified as having Hispanic/Latino background, the lar-
gest groups being Central American (n = 1732), Cuban
(n = 2348), Dominican (n = 1473), Mexican (n = 6472),
Puerto-Rican (n = 2728), and South American
(n = 1072). Baseline lipids levels were measured for par-
ticipants during clinical examinations from 2008 to
2011. Of the study population, 12,803 individuals both
consented for genotyping and were successfully
genotyped. The HCHS/SOL was approved by institu-
tional review boards at participating institutions, and
written informed consent was obtained from all
participants.
Genotyping and imputation
DNA extracted from whole blood was genotyped on an
Illumina custom array consisting of the Illumina Omni
2.5 M array (HumanOmni2.5-8v1-1) and ~150,000 cus-
tom SNPs identified to capture Amerindian genetic vari-
ation. Sample-level quality and identity checks, and
SNP-level quality filtering resulted in a total of 12,803
samples with a missing call rate < 1% and 2,232,944 in-
formative SNPs with a missing call rate < 2%. Imput-
ation with the 1000 Genomes Project phase 1 multi-
ethnic reference panel using SHAPEIT2 pre-phasing and
IMPUTE2 imputation resulted in 25,568,744 imputed
variants. Genotype quality control, imputation, related-
ness, and PC estimation methods are described in more
detail in Conomos et al., 2016 [18].
Lipids phenotype outcomes
Twelve-hour fasting blood samples were collected ac-
cording to standard protocols and used to measure
serum total cholesterol, triglycerides, and HDL levels
[19]. LDL levels were estimated according to the Friede-
wald equation [20]. An inventory of all prescription and
over-the-counter medication each participant had used
in the previous four weeks was taken at the clinic exam-
ination. We retained individuals taking lipid-lowering
medications, first because these individuals are likely to
carry variants that result in dyslipidemia, and second, to
maximize the sample size. Therefore, we adjusted lipid
levels by adding constant values for participants who re-
ported taking lipid-lowering medications (statins,
fibrates, bile acid sequestrants, niacin, and cholesterol
absorption inhibitors) as has been done previously [15].
This adjustment was made in an attempt to restore the
lipid value to what it was before taking the medications.
The constant value depended on the specific type of
medications used (Additional file 1: Table S1) [4, 21, 22].
If multiple medications were used, we applied the cor-
rection factor with the largest effect (e.g. for someone on
statins and fibrates, we adjusted their triglycerides level
by +57.1 mg/dL and their LDL by +49.9 mg/dL). To as-
sess potential biases from applying a medication correc-
tion, we performed sensitivity analyses with known lipid
loci, where we included all individuals and 1) applied a
correction factor by adding constant values for partici-
pants who reported taking lipid-lowering medications,
or 2) adjusted for lipid-lowering medications using a
separate covariate for each lipid drug. Results varied lit-
tle regardless of how we accounted for users of lipid-
lowering medication (Additional file 2: Fig. S1). One
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extreme triglyceride level was excluded from analysis
(adjusted triglycerides = 6366 mg/dL). Triglyceride levels
were log-transformed (after medication adjustment) for
association analyses. All other lipid traits were normally
distributed.
Genetic association analyses
Tests for genetic associations were performed using linear
mixed models (LMMs), adjusting for population structure
using the first five genetic principal components (PCs)
and “genetic analysis group” as fixed effects. Genetic ana-
lysis groups were defined from a combination of genetic
PCs and self-identified ancestry [18]. We adjusted for
sampling design using a function (determined by AIC) of
the sampling weights as a fixed effect, and adjusted for
correlation among individuals due to shared community
(group block), household, and genetic relatedness (kin-
ship) using random effects. Expected allelic dosages were
used for imputed SNPs in the association analyses, and re-
sults were filtered according to the effective minor allele
count accounting for imputation quality. A detailed de-
scription of genetic association analyses in the HCHS/
SOL can be found in Conomos et al., 2016 [18]. Signifi-
cance was assessed using a genome-wide significance
threshold of p-value ≤5 × 10−8. A significant locus was de-
fined as a 1 Mb region (+/−500 kb) around the most sig-
nificant SNP (index SNP).
Conditional analyses
To evaluate the possibility of novel lipid loci within
previously established association regions, we applied
the same LMMs for association testing while condi-
tioning on previously reported index SNPs associated
with any of the four lipids traits [6–15] (i.e. by in-
cluding them as covariates), under the assumption of
pleiotropy (Additional file 1: Table S2). In this table a
‘primary’ SNP was defined as the first identified (pub-
lished) SNP in a given 1 Mb (+/− 500 kb) region,
and an established ‘secondary’ SNP was defined as
any published SNPs inside of a ‘primary’ SNP region.
All primary SNPs are independent from each other
and from all secondary SNPs, but not all secondary
SNPs are independent from each other in a given re-
gion. SNPs that remained or became genome-wide
significant after conditioning on known loci were con-
sidered for replication testing in other cohorts. In the
results presented here, we defined potentially novel
primary signals as previously-unreported SNPs that
fell outside of a known index SNP region. We defined
potentially novel secondary signals as previously-
unreported if the SNP fell inside of a known index
SNP region but was independent of all other SNPs
within that region.
Replication of potential novel signals
Eight SNPs that reached genome-wide significance, sep-
arate from previously reported signals, were tested for
replication in independent studies. These consisted of
samples from Mexican Americans from Starr County,
Texas and individuals from Mexico City [9], women in
the Women’s Health Initiative Study (WHI) who self-
reported Hispanic/Latino ancestry [23], and a subset of
cohorts from the GUARDIAN consortium consisting of
participants of Mexican ancestry [Insulin Resistance
Atherosclerosis Study [24], Insulin Resistance Athero-
sclerosis Family Study (IRAS-FS) [25], Hypertension-
Insulin Resistance (HTN-IR) Family study [26], and
Mexican-American Coronary Artery Disease (MACAD)
study] [27]. We also sought to generalize novel associ-
ation signals to populations of European or African an-
cestry, including individuals in the Atherosclerosis Risk
in Communities (ARIC) study [28] and the Women’s
Health Initiative Study (WHI) [23]. We selected individ-
uals of different ancestries because many of the SNPs
followed-up for replication testing were rare in the
HCHS/SOL, but slightly more frequent in other ances-
tries based on reference samples including African
(AFR) or European (EUR) individuals.
In each replication study, fasting lipid levels were col-
lected using standardized procedures and lipid pheno-
types were adjusted for medication use in a manner
similar to the HCHS/SOL analyses, except for GUARD-
IAN who did not adjust for lipid medication due to <5%
of use within each study. Each study used linear regres-
sion stratified by ancestry (i.e. European, African, and
Hispanic/Latino) to test for SNP-trait associations while
adjusting for covariates including age, sex, and PCs 1-10,
and obtained p-values from the Wald test. Family-based
cohorts adjusted for pedigree structure. We then per-
formed both ancestry-specific and a combined ancestries
inverse normal fixed effects meta-analyses. To test the
hypothesis of an association in the replication studies,
we used the framework of Sofer et al. [29] and calculated
a false discovery rate (FDR)-controlling directional r-
value for each tested association, based on its p-value in
both the HCHS/SOL and the replication study. FDR was
controlled at the 0.05 level in calculating the r-values in
each replication analysis, and we concluded that an asso-
ciation replicated in a given follow-up meta-analysis if it
had an r-value ≤0.05.
Heritability estimation
To estimate the heritability of each lipid trait in the
HCHS/SOL sample, we estimated kinship coefficients
within a maximal set of unrelated participants, using the
complete set of genotyped SNPs with minor allele fre-
quencies (MAF) ≥1% (~1.7 million SNPs). Unrelated in-
dividuals were defined as those with estimated kinship
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coefficients smaller than 2-11/2, i.e. more distant than
fourth degree relatives. We estimated heritability as the
proportion of the total phenotypic variance explained by
the kinship coefficient matrix, calculated in a LMM as
described above. The LMM was adjusted for the same
fixed and random effects as described above in genetic
association analyses, with the exception that a slightly
different kinship matrix was used. Heritability p-values
were calculated based on the likelihood ratio test, and
95% confidence intervals based on the normal approxi-
mation to the distribution of the ratio between the kin-
ship variance components and the total variance.
Generalization of previously reported SNP-trait
associations
We identified nine studies that previously reported SNP-
lipid trait associations in cohorts of European ancestry
[5–7], and other ancestries [8–13]. We investigated
whether the 347 SNP-trait associations (some SNPs
overlap with more than one lipid trait, Additional file 1:
Table S2) reported in these studies generalized to His-
panics/Latinos in the HCHS/SOL sample. For each
known lipid-associated SNP, we calculated an FDR-
controlling directional r-value based on both the p-value
reported in the literature, and the HCHS/SOL associ-
ation testing results. We computed r-values for each
study (i.e. the study in the literature and the HCHS/SOL
study) and trait separately. An association was general-
ized if its corresponding r-value was smaller than 0.05.
For each lipid trait, we also computed a genetic risk score
for the SNPs that did not generalize to determine the im-
portance of power on negative results. Specifically, for each
trait, we summed the trait-increasing alleles of all the non-
generalized SNPs, and tested the resulting risk score in the
linear mixed model described above. A p-value <0.05 indi-
cates that, while not formally generalized, some of the SNPs
are likely associated with the trait in Hispanics/Latinos.
Results
The sample included participants (~59% female) who
were on average 46.1 years of age, ranging from 18 to
74 years (Table 1). Approximately 12.3% of the individ-
uals reported using lipid-lowering medications. Mean
measured total cholesterol, LDL, HDL, and triglycerides
were 199.49 (±43.6) mg/dl, 122.85 (±36.54) mg/dl, 49.07
(±13.09), and 139.75 (±101.03) mg/dl, respectively.
Trait-specific association analyses
The genomic inflation factors for the association analyses
of HDL, LDL, and total cholesterol were each 1.03 and for
triglycerides was 1.00 (Additional file 2: Fig. S2), indicating
adequate control of population stratification. In these
trait-specific analyses, we identified 14, 16, 17, and 10
genome-wide significant independent loci (+/− 500 kb
from index SNP) associated with HDL, LDL, total choles-
terol, and triglycerides, respectively (Additional file 1:
Table S3). We tested these loci for novelty as follows.
Conditional analyses
To identify potentially novel signals, we conditioned the
trait-specific association analyses on 344 previously iden-
tified variants for the four lipid traits in European, Asian,
African, and Hispanic/Latino samples. We observed
eight new independent genome-wide significant associ-
ation signals in total; four for HDL, one for LDL, two
for total cholesterol, and one for triglycerides (Add-
itional file 1: Table S4).
Two of the four HDL signals were potentially novel
secondary signals as they fell within +/− 500 kb of a
known locus, one in APOA5/A1 (rs184637772,
MAF = 0.002) and one in DAGLB (rs77071750,
MAF = 0.003). The additional six signals were poten-
tially novel primary signals, as they fell outside +/−
500 kb of known loci: two signals associated with HDL,
one in SYNE1 (rs78768891, MAF = 0.007) and one in
AUTS2 (rs191891263, MAF = 0.003); one signal associ-
ated with LDL located near DNAL1 (rs149886784,
MAF = 0.002); one signal associated with triglycerides
near SMOC2 (rs77635931, MAF = 0.002); and two sig-
nals associated with total cholesterol, in CD86
(rs114378860, MAF = 0.007), and near DNAH5
(rs183336356, MAF = 0.002).
Table 1 Descriptives of analytic sample for each lipid trait
HDL LDL Triglycerides Total Cholesterol
Sample size, N 12,730 12,467 12,730 12,731
% Female 58.93 59.46 58.93 58.93
Mean age, years 46.1 (13.8) 46.1 (13.8) 46.1 (13.8) 46.1 (13.8)
% reporting use of lipid-lowering medications 12.27 12.25 12.26 12.27
Mean (SD) unadjusted lipid value (mg/dL) 49.07 (±13.09) 122.85 (±36.54) 139.75 (±101.03) 199.49 (±43.6)
Mean (SD) lipid value (mg/dL), adjusted for medication usea 48.73 (±13.17) 128.87 (±38.13) 142.6 (±102.34) 205.78 (±45.66)
Natural log of adjusted lipid value (mg/dL)b 4.79 (±0.56)
a A constant was added to the lipid value based on type medication use. See Additional file 1: Table S1
b Only triglycerides were natural log transformed. Lipid values were corrected for medication use prior to natural log transformation
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Replication of potential novel signals
These potentially novel signals failed to replicate in our
combined replication samples from GUARDIAN, the
ARIC study, and WHI study, and an existing Mexican
ancestry meta-analysis (Table 2). They also failed to rep-
licate when we tested them in each separate meta-
analyzed ancestry of the replication samples (i.e. Euro-
pean only, African only, and Hispanic only). Our power
to replicate an effect in for each signal based on the rep-
lication meta-analyzed sample was less than 80% power
except for the signal in DAGLB (rs77071750), which was
94%. This was partially from the larger replication sam-
ple available for thes signal and slightly higher MAF for
in the combined replication sample, 0.08% versus 0.02%
for HCHS/SOL. The signal in DAGLB (rs77071750)
nearly reached significance in the combined meta-
analyzed sample at r-value = 0.08. Figure 1 shows this
signal before and after conditional analyses on the
known SNP, rs702485.
Heritability estimates of lipid traits
SNP-based heritability was estimated from a variance-
component analysis performed with a subset of 10,264
individuals that excluded close familial relatives. The es-
timated heritability was 22% for total cholesterol, 24%
for triglycerides, 24% for HDL, and 21% for LDL
(Table 3). These estimates are population-specific, but
comparable to what has been reported before using SNP
data in large European ancestry populations [6, 8].
Generalization
We tested all known signals that had been previously as-
sociated with a given lipid trait for generalization in the
HCHS/SOL using directional r-values. For total choles-
terol, we tested 121 previously published variants in 74
regions. Of these, 36 regions generalized to the HCHS/
SOL (Additional file 1: Tables S5, S9), two of which
(HLA and PLEC1 regions) were based on secondary sig-
nals only. For LDL, we tested 128 published variants in
60 regions (Additional file 1: Tables S6, S9). Of these, 28
generalized to HCHS/SOL, one of which (LDLRAP1)
was based on a secondary signal only. For HDL, we
tested 139 published variants in 75 regions. Thirty-one
of the 75 regions generalized to the HCHS/SOL (Add-
itional file 1: Tables S7, S9), one of which (LILRA3) was
based on secondary signals only. Finally, we tested 79
published triglycerides variants in 44 regions (Additional
file 1: Tables S8, S9). Of these, 19 regions generalized to
the HCHS/SOL, one of which was based on a secondary
signal (HLA). In general, 50% of the tested SNPs gener-
alized, overall and by ancestry, notably 11 out of the 12
SNPs previously identified in studies of Hispanic/Latino
ancestry replicated in HCHS/SOL.
We defined a region as generalized if at least one of
the variants in the region generalized to HCHS/SOL.
Figure 2 shows the number of generalized and non-
generalized regions per trait. A region could have gener-
alized because the primary SNP generalized, because a
secondary SNP generalized, or because both did. There
were nine regions in which the primary SNP did not
generalize, while a secondary SNP did generalize (4 re-
gions for HDL, 2 regions for total cholesterol, 1 region
for LDL, 2 regions for triglycerides). In 49 generalized
regions, only the primary SNP generalized, but no add-
itional secondary SNP generalized. In the 48 remaining
generalized regions, both the primary SNP and at least
one secondary SNP generalized. Across all associations
(regardless of regions), 43% of the primary SNPs (109 of
253 SNPs) generalized, and 59% of the secondary SNPs
(123 of 209 total SNPs) generalized.
Finally, for each trait, to assess the possibility that add-
itional previously reported associations exists in the
HCHS/SOL, but could not be generalized due to lack of
power, we calculated a score defined by the sum of all
trait-increasing alleles of all the non-generalized SNPs.
The results were highly significant: the p-value for gen-
etic scores by trait were: HDL p-value 8.6 × 10−26, LDL
p-value 1.4 × 10−29, triglycerides p-value 6.9 × 10−41, and
total cholesterol p-value 3.5 × 10−15. These results sug-
gest that some of the non-generalized SNPs are truly as-
sociated with their respective trait in the HCHS/SOL,
but did not generalize individually due to lack of power.
Discussion
We performed a GWAS of four lipid traits in a sample
of approximately 12,800 Hispanic/Latino participants of
HCHS/SOL. Of eight potentially novel loci identified
from conditioning on known loci in the literature, we
were unable to replicate any SNPs in several diverse rep-
lication cohorts. We demonstrated that >50% of the pre-
viously identified GWAS loci for lipid traits generalized
to HCHS/SOL, which has important implications for
further study of lipids genetics in Hispanics/Latinos.
We failed to replicate the eight potentially novel sig-
nals, possibly because of the very low minor allele fre-
quencies, which ranged from 0.2% to 0.7% in the HCHS/
SOL sample. At these frequencies and the identified ef-
fect sizes, our replication samples were not powered at
80% to replicate these effects. Studies in larger samples
of Hispanic/Latino or diverse ancestry participants are
needed to further investigate these low frequency vari-
ants. The signal that came closest to replicating was a
signal in DAGLB (rs77071750 with MAF = 0.003) associ-
ated with HDL. rs77071750 lies about 130 kb from the
primary signal, rs702485, and is monomorphic in popu-
lations of European ancestry but has a frequency of
about 4% in populations of African ancestry. The SNP
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rs77071750 is intronic to GRID2IP, which encodes the
glutamate receptor, ionotropic, delta 2 (Grid2) interacting
protein that links GRID2 with actin cytoskeleton signaling
molecules. As for the other potentially novel SNPs, while
rs184637772 did not replicate, it has some interesting biol-
ogy. It is intronic to APOC3 has histone marks H3K4me3,
H3K9ac indicative of promoter activity in liver and intes-
tine. Other potentially novel SNPs appear less interesting.
Generalization analysis revealed that >50% of previ-
ously established lipid variants identified in GWAS of
European-, Hispanic/Latino-, East Asian-, or African-
descent populations generalized to HCHS/SOL based on
an r-value <0.05, which accounts for agreement in the
direction of effect. This fraction is much greater than ex-
pected by chance for each trait (binomial test for con-
sistent direction of effect and an r-value <0.05 reached
p-values < 6.5 × 10−31 for each trait). We might expect
that loci that are directionally consistent and generalize
are also likely to be functionally involved in lipid biology
across diverse population groups. On the other hand,
Hispanic/Latino descent populations have a fair amount
of European ancestry and this could also be a reason for
generalization. Failure to generalize can occur because
the power for discovery in the HCHS/SOL was low, due
Fig. 1 LocusZoom plots of the novel signal identified and replicated in the DAGLB locus (index variant rs77071750) that is independent of the
known signal at rs702485. The top half of the figure “Primary analysis” shows the -log10 p-values for all variants before conditioning on the known
variant. The bottom half of the figure “Conditioned on known SNPs” shows the -log10 p-values for all variants after conditioning on the known
variant, rs702485
Table 3 Heritability estimates for each lipid trait
Trait Genetic Variance explaineda
[Lower 95CI, Upper 95CI]
Pvalue (Genetic
variance)
Variance explained by sampling
unit (block group)
Variance explained
by household
Variance explained by
environment
Total
cholesterol
0.22 [0.15, 0.29] <0.001 0.002 0.047 0.731
Triglycerides 0.24 [0.18, 0.31] <0.001 0.003 0.027 0.73
HDL-
cholesterol
0.24 [0.17, 0.3] <0.001 0.012 0.056 0.694
LDL-
cholesterol
0.21 [0.14, 0.27] <0.001 0.001 0.058 0.735
Lower 95CI: lower 95% confidence interval, Upper 95CI: upper 95% confidence interval
a Genetic Variance: is the proportion of variance accounted for by relatedness
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to either low MAF or differences in LD across popula-
tions, chip coverage of the relevant locus, or because the
originally published variant was a false positive.
We note that of the 12 SNPs (11 for HDL and 1 for
triglycerides) that were previously identified in Hispanic/
Latino samples, 11 generalized to HCHS/SOL. Ten of
the 12 SNPs identified in Hispanic/Latino samples lie in
previously established 1 Mb regions identified in Euro-
peans, while two SNPs (both associated with HDL),
rs148533712 (in RORA) and rs78557978 (near UGT8),
lie in 1 Mb regions first identified in Hispanics/Latino
samples. However, neither rs148533712 nor rs78557978
generalized to HCHS/SOL. Of the 10 SNPs that are in
previously identified 1 Mb regions all of which general-
ized to HCHS/SOL), five associated with HDL are in LD
(R2 > 0.5) with another previously identified European
SNP or signal (rs2278426 in LOC55908 and the
ANGPTL8 known region, rs1532624 near CETP,
rs261334 and rs1077835 in/near LIPC, and rs4149310 in
ABCA1). Except for rs4149310, all have no remaining
signal (p-values > 0.05) after conditional analyses. How-
ever, rs4149310 still has some signal remaining, specific-
ally an unconditioned p-value =1.52 × 10−12 that
becomes p-value = 5.6 × 10−08 after conditioning on all
known SNPs. An additional SNP associated with HDL,
rs2472386 in the ABCA1 region, identified in a different
Hispanic sample than rs4149310, is in moderate LD with
rs4149310 (r2 = 0.6) and in low LD with a nearby Euro-
pean identified SNP, rs2853579 (r2 = 0.3). However, be-
tween these 3 SNPs (i.e. rs2853579, rs4149310, and
rs2472386) there is a distinct haplotype (TTG) that is
identified in the 1000 genomes phase 3 AMR popula-
tions at 1% frequency and not found in the EUR popula-
tions. Two SNPs associated with HDL, rs9282541 a
missense variant in the ABCA1 gene, and rs11216230 an
intronic variant in SIK3 gene (also in the APOA5/
APOA1 known region) are Hispanic-specific signals and
independent of all other known signals in their respect-
ive regions [12, 13]. We replicate these two signals for
the first time in another Hispanic sample. Within the
APOA5/APOA1 region for the HDL, rs11216230 is the
only SNP in a secondary signal that generalized. The
other 4 SNPs in secondary signals did not replicate. Fi-
nally, a Hispanic-specific signal in the CLIP2 region,
HDL
LDL
TC
TG
0
30
60
90
0
30
60
90
0
30
60
90
0
30
60
90
Al
l r
eg
ion
s
Pr
im
ar
y &
 S
ec
on
da
ry
On
ly 
pr
im
ar
y
On
ly 
se
co
nd
ar
y
re
gi
on
s
Generalized
Not generalized
Fig. 2 The number of generalized and non-generalized regions per
trait. The number of generalized regions are divided according to
the number of region generalizations that are due solely to
generalization of the primary SNP (while other secondary SNPs did not
generalize): “Only primary”; solely due to generalizations of a (at least
one) secondary SNP (while the primary SNP did not generalize): “Only
secondary”; and the number of regions in which both the primary SNP
generalized, and at least one secondary SNP: “Primary & Secondary”.
Those that generalized are shown in blue and those that did not
generalize are shown in grey
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rs8102280, an intronic variant in the MAU2 gene, gener-
alized to the HCHS/SOL sample. This signal has been
replicated previously [9].
Conclusions
In summary, we did not identify any novel lipid-
associated loci, but did demonstrate that greater than
half of previously identified GWAS loci for lipid traits
generalized to HCHS/SOL. These results suggest that
the genetic architecture of lipid levels includes several
loci that are shared across different population groups. It
is also possible that the generalization of European sig-
nals is due to the large fractions of European ancestry in
Hispanics. Larger sample sizes are required for further
investigations of potentially novel loci in Hispanic
populations.
Additional files
Additional file 1: Supplementary Tables. (ODS 129 kb)
Additional file 2: Supplementary Figures. (DOCX 112 kb)
Acknowledgements
HCHS/SOL: We thank the participants and staff of the Hispanic Community
Health Study/Study of Latinos (HCHS/SOL) for their contributions to this
study. The baseline examination of HCHS/SOL was carried out as a
collaborative study supported by contracts from the NHLBI to the University
of North Carolina (N01-HC65233), University of Miami (N01-HC65234), Albert
Einstein College of Medicine (N01-HC65235), Northwestern University (N01-
HC65236), and San Diego State University (N01-HC65237). The following
institutes, centers, and offices contributed to the first phase of HCHS/SOL
through a transfer of funds to the NHLBI: National Institute on Minority
Health and Health Disparities, National Institute on Deafness and Other
Communication Disorders, National Institute of Dental and Craniofacial
Research (NIDCR), National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK), National Institute of Neurological Disorders and Stroke, and
NIH Office of Dietary Supplements. The Genetic Analysis Center at the
University of Washington was supported by NHLBI and NIDCR contracts
(HHSN268201300005C AM03 and MOD03). Additional analysis support was
provided by NIDDK grant 1R01DK101855-01, NHLBI grant N01HC65233, and
AHA grant 13GRNT16490017. Genotyping efforts were supported by the NIH
Department of Health and Human Services (HSN26220/20054C), National
Center for Advancing Translational Science Clinical Translational Science
Institute (UL1TR000124), and NIDDK Diabetes Research Center (DK063491).
This manuscript has been reviewed by the HCHS/SOL Publications
Committee for scientific content and consistency of data interpretation with
previous HCHS/SOL publications.
ARIC: The Atherosclerosis Risk in Communities Study is carried out as a
collaborative study supported by National Heart, Lung, and Blood Institute
contracts N01-HC-55015, N01-HC-55016, N01-C-55018, N01-HC-55019,
N01-HC-55020, N01-HC-55021, N01-HC-55022, R01HL087641, R01HL59367
and R01HL086694; National Human Genome Research Institute contract
U01HG004402; and National Institutes of Health contract
HHSN268200625226C. Infrastructure was partly supported by Grant Number
UL1RR025005, a component of the National Institutes of Health and NIH
Roadmap for Medical Research. The project described was supported by
Grant Number UL1 RR 025005 from the National Center for Research Re-
sources (NCRR), a component of the National Institutes of Health (NIH) and
NIH Roadmap for Medical Research, and its contents are solely the responsi-
bility of the authors and do not necessarily represent the official view of
NCRR or NIH. The authors thank the staff and participants of the ARIC Study
for their important contributions.
WHI: Funding support for the “Epidemiology of putative genetic variants: The
Women’s Health Initiative” study is provided through the NHGRI grants
HG006292 and HL129132. The WHI program is funded by the National Heart,
Lung, and Blood Institute, National Institutes of Health, U.S. Department of
Health and Human Services through contracts HHSN268201100046C,
HHSN268201100001C, HHSN268201100002C, HHSN268201100003C,
HHSN268201100004C, and HHSC271201100004C. The authors thank the WHI
investigators and staff for their dedication, and the study participants for
making the program possible. A full listing of WHI investigators can be
found at: https://www.whi.org/about/SitePages/Study%20Organization.aspx.
Mexican ancestry meta-analysis sample: In Mexico, this work was supported
by the Fondo Sectorial de Investigación en Salud y Seguridad Social (SSA/
IMSS/ISSSTE-CONACYT) project 150352, Temas Prioritarios de Salud Instituto
Mexicano del Seguro Social 2014-FIS/IMSS/PROT/PRIO/14/34, and the
Fundación IMSS. We thank Jorge Gutierrez Cuevas, Jaime Gómez Zamudio
and Araceli Méndez Padrón for technical support. In Canada, the research
was supported by a Canadian Institutes of Health Research (CIHR) operating
grant to EJP, and also by funding from the Banting and Best Diabetes Centre
to EJP. The work in the Starr County cohort was supported by NIH grants
HL102830, DK085501, DK073541, DK020595, AI085014 and funds from the
University of Texas Health Science Center at Houston.
GUARDIAN consortium: Funding. This research was supported by the
National Institutes of Health: the GUARDIAN Consortium (DK085175), IRASFS
(HL060944, HL061019, HL060919, and HG007112), IRAS (HL047887, HL047889,
HL047890, HL47902), MACAD (HL088457 and DK079888), and HTN-IR
(HL0697974 and DK079888). The provision of genotyping data was
supported in part by UL1-TR-000124 (Clinical and Translational Science
Institute) and DK063491. Computing resources were provided in part by the
Wake Forest School of Medicine Center for Public Health Genomics.
Funding
NHLBI to the University of North Carolina (N01-HC65233). The Genetic
Analysis Center at the University of Washington was supported by NHLBI
and NIDCR contracts (HHSN268201300005C AM03 and MOD03). Additional
analysis support was provided by 1R01DK101855-01 and 13GRNT16490017.
Availability of data and materials
Genotype and imputed data of the HCHS/SOL can be requested via dbGaP
study accession phs000880. Phenotype data can be requested via dbGaP
study accession phs000810.
Authors’ contributions
MG, LSE, AEJ, TS, KEN led the analysis and wrote the manuscript. LSE and TS
performed the analyses. CCL TS, and KEN supervised the work. EP, JEB, NDP,
CG, QD, AVS, MC, ACM, EB, EW, CK, AR, YL, CDL, LEW, JMN, KDT, and Y-DIC
participated in the replication effort. All authors reviewed the manuscript. All
authors read and approved the final manuscript.
Ethics approval and consent to participate
The HCHS/SOL was approved by institutional review boards at participating
institutions, and written informed consent was obtained from all participants.
Consent for publication
Not applicable.
Competing interests
The authors have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Epidemiology, Gillings School of Global Public Health,
University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
2Department of Biostatistics, University of Washington, Seattle, WA, USA.
3Biomedical and Translational Informatics, Geisinger Health, Danville, PA, USA.
4Department of Anthropology, University of Toronto at Mississauga,
Mississauga, ON, Canada. 5Vanderbilt Genetics Institute, Vanderbuilt
University, Nashville, TN, USA. 6Department of Biochemistry, Wake Forest
University School of Medicine, Winston-Salem, NC, USA. 7Molecular Genetics
and Genomics Program, Wake Forest University School of Medicine,
Winston-Salem, NC, USA. 8Department of Genetics, University of North
Graff et al. Lipids in Health and Disease  (2017) 16:200 Page 10 of 12
Carolina at Chapel Hill, Chapel Hill, NC, USA. 9Unidad de Investigacion
Medica en Bioquimica, Hospital de Especialidades, CMNSXX1-IMSS, Mexico
City, Mexico. 10Department of Epidemiology, Human Genetics and
Environmental Sciences, University of Texas Health Science Center at
Houston, Houston, TX, USA. 11Department of Medicine, University of North
Carolina at Chapel Hill, Chapel Hill, NC, USA. 12Fred Hutchinson Cancer
Research Center, Public Health Sciences, Seattle, WA, USA. 13Department of
Medicine and Public Health Sciences, Wake Forest University School of
Medicine, Winston-Salem, NC, USA. 14Graduate School of Public Health, San
Diego State University, San Diego, CA, USA. 15Department of Biostatistical
Sciences, Wake Forest University School of Medicine, Winston-Salem, NC,
USA. 16Department of Epidemiology, Colorado School of Public Health,
University of Colorado Denver, Aurora, CO, USA. 17Institute for Translational
Genomics and Population Sciences and Department of Pediatrics, Los
Angeles BioMedical Research Institute at Harbor-UCLA Medical Center,
Torrance, CA, USA. 18National Heart, Lung, and Blood Institute, Bethesda, MD
20892, USA. 19Genetics and Genomic Sciences, Icahn School of Medicine at
Mount Sinai, New York, NY, USA. 20The Charles Bronfman Institute for
Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York,
NY, USA. 21Division of Sleep and Circadian Disorders, Brigham and Women’s
Hospital, Boston, MA, USA. 22Department of Medicine, Harvard Medical
School, Boston, MA, USA.
Received: 20 July 2017 Accepted: 4 October 2017
References
1. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J 3rd. Factors of risk in
the development of coronary heart disease–six year follow-up experience.
The Framingham study. Ann Intern Med. 1961;55:33–50.
2. Rodriguez, C. J., M. L. Daviglus, K. Swett, H. M. Gonz??lez, L. C. Gallo, S.
Wassertheil-Smoller, A. L. Giachello, Y. Teng, N. Schneiderman, G. A. Talavera,
and R. C. Kaplan. 2014. Dyslipidemia patterns among Hispanics/Latinos of
diverse background in the United States. Am J Med 127: 1186–1194.e1.
3. Toth PP, Potter D, Ming EE. Prevalence of lipid abnormalities in the United
States: the National Health and nutrition examination survey 2003-2006. J
Clin Lipidol. 2012;6:325–30.
4. Third Report of the National Cholesterol Education Program (NCEP). Expert
panel on detection, evaluation, and treatment of high blood cholesterol in
adults (adult treatment panel III) final report. Circulation. 2002;106:3143–421.
5. Fenger M. Heritability and genetics of lipid metabolism. Futur Lipidol. 2007;2:433–44.
6. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S,
Ganna A, Chen J, Buchkovich ML, Mora S, Beckmann JS, Bragg-Gresham JL,
Chang H-Y, Demirkan A, Den Hertog HM, Do R, Donnelly LA, Ehret GB, Esko
T, Feitosa MF, Ferreira T, Fischer K, Fontanillas P, Fraser RM, Freitag DF,
Gurdasani D, Heikkila K, Hypponen E, Isaacs A, Jackson AU, Johansson A,
Johnson T, Kaakinen M, Kettunen J, Kleber ME, Li X, Luan J, Lyytikainen L-P,
Magnusson PKE, Mangino M, Mihailov E, Montasser ME, Muller-Nurasyid M,
Nolte IM, O’Connell JR, Palmer CD, Perola M, Petersen A-K, Sanna S, Saxena
R, et al. Discovery and refinement of loci associated with lipid levels. Nat
Genet. 2013;45:1274–83.
7. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M,
Pirruccello JP, Ripatti S, Chasman DI, Willer CJ, Johansen CT, Fouchier SW,
Isaacs A, Peloso GM, Barbalic M, Ricketts SL, Bis JC, Aulchenko YS, Thorleifsson
G, Feitosa MF, Chambers J, Orho-Melander M, Melander O, Johnson T, Li X,
Guo X, Li M, Shin Cho Y, Jin Go M, Jin Kim Y, Lee J-Y, Park T, Kim K, Sim X,
Twee-Hee Ong R, Croteau-Chonka DC, Lange LA, Smith JD, Song K, Hua Zhao
J, Yuan X, Luan J, Lamina C, Ziegler A, Zhang W, Zee RYL, Wright AF, Witteman
JCM, Wilson JF, Willemsen G, et al. Biological, clinical and population relevance
of 95 loci for blood lipids. Nature. 2010;466:707–13.
8. Tada H, Won H-H, Melander O, Yang J, Peloso GM, Kathiresan S. Multiple
associated variants increase the heritability explained for plasma lipids and
coronary artery disease. Circ Cardiovasc Genet. 2014;7:583–7.
9. Below JE, Parra EJ, Gamazon ER, Torres J, Krithika S, Candille S, Lu Y,
Manichakul A, Peralta-Romero J, Duan Q, Li Y, Morris AP, Gottesman O,
Bottinger E, Wang X-Q, Taylor KD, Ida Chen Y-D, Rotter JI, Rich SS, Loos RJF,
Tang H, Cox NJ, Cruz M, Hanis CL, Valladares-Salgado A. Meta-analysis of
lipid-traits in Hispanics identifies novel loci, population-specific effects, and
tissue-specific enrichment of eQTLs. Sci Rep. 2016;6:19429.
10. Dumitrescu L, Carty CL, Taylor K, Schumacher FR, Hindorff LA, Ambite JL,
Anderson G, Best LG, Brown-Gentry K, Bůžková P, Carlson CS, Cochran B, Cole SA,
Devereux RB, Duggan D, Eaton CB, Fornage M, Franceschini N, Haessler J,
Howard BV, Johnson KC, Laston S, Kolonel LN, Lee ET, MacCluer JW, Manolio TA,
Pendergrass SA, Quibrera M, Shohet RV, Wilkens LR, Haiman CA, Le Marchand L,
Buyske S, Kooperberg C, North KE, Crawford DC. Genetic determinants of lipid
traits in diverse populations from the population architecture using genomics
and epidemiology (PAGE) study. PLoS Genet. 2011;7(6):e1002138.
11. Elbers CC, Guo Y, Tragante V, van Iperen EPA, Lanktree MB, Castillo BA, Chen F,
Yanek LR, Wojczynski MK, Li YR, Ferwerda B, Ballantyne CM, Buxbaum SG, Chen
YDI, Chen WM, Cupples LA, Cushman M, Duan Y, Duggan D, Evans MK,
Fernandes JK, Fornage M, Garcia M, Garvey WT, Glazer N, Gomez F, Harris TB,
Halder I, Howard VJ, Keller MF, Kamboh MI, Kooperberg C, Kritchevsky SB,
LaCroix A, Liu K, Liu Y, Musunuru K, Newman AB, Onland-Moret NC, Ordovas J,
Peter I, Post W, Redline S, Reis SE, Saxena R, Schreiner PJ, Volcik KA, Wang X,
Yusuf S, Zonderland AB, et al. Gene-centric meta-analysis of lipid traits in
African, east Asian and Hispanic populations. PLoS One. 2012;7(12):e50198.
12. Weissglas-Volkov D, Aguilar-Salinas CA, Nikkola E, Deere KA, Cruz-Bautista I,
Arellano-Campos O, Munoz-Hernandez LL, Gomez-Munguia L, Ordonez-
Sanchez ML, Reddy PMVL, Lusis AJ, Matikainen N, Taskinen M-R, Riba L,
Cantor RM, Sinsheimer JS, Tusie-Luna T, Pajukanta P. Genomic study in
Mexicans identifies a new locus for triglycerides and refines European lipid
loci. J Med Genet. 2013;50:298–308.
13. Ko A, Cantor RM, Weissglas-Volkov D, Nikkola E, Reddy PMVL, Sinsheimer JS,
Pasaniuc B, Brown R, Alvarez M, Rodriguez A, Rodriguez-Guillen R, Bautista
IC, Arellano-Campos O, Muñoz-Hernández LL, Salomaa V, Kaprio J, Jula A,
Jauhiainen M, Heliövaara M, Raitakari O, Lehtimäki T, Eriksson JG, Perola M,
Lohmueller KE, Matikainen N, Taskinen M-R, Rodriguez-Torres M, Riba L,
Tusie-Luna T, Aguilar-Salinas CA, Pajukanta P. Amerindian-specific regions
under positive selection harbour new lipid variants in Latinos. Nat Commun.
2014;5:3983.
14. Wu Y, Waite LL, Jackson AU, Sheu WH-H, Buyske S, Absher D, Arnett DK,
Boerwinkle E, Bonnycastle LL, Carty CL, Cheng I, Cochran B, Croteau-Chonka
DC, Dumitrescu L, Eaton CB, Franceschini N, Guo X, Henderson BE, Hindorff
LA, Kim E, Kinnunen L, Komulainen P, Lee W-J, Le Marchand L, Lin Y,
Lindstrom J, Lingaas-Holmen O, Mitchell SL, Narisu N, Robinson JG,
Schumacher F, Stancakova A, Sundvall J, Sung Y-J, Swift AJ, Wang W-C,
Wilkens L, Wilsgaard T, Young AM, Adair LS, Ballantyne CM, Buzkova P,
Chakravarti A, Collins FS, Duggan D, Feranil AB, Ho L-T, Hung Y-J, Hunt SC,
Hveem K, et al. Trans-ethnic fine-mapping of lipid loci identifies population-
specific signals and allelic heterogeneity that increases the trait variance
explained. PLoS Genet. 2013;9:e1003379.
15. Zubair N, Graff M, Ambite JL, Bush WS, Kichaev G, Lu Y, Manichaikul A, Sheu
WH-H, Absher D, Assimes TL, Bielinski SJ, Bottinger EP, Buzkova P, Chuang L-M,
Chung R-H, Cochran B, Dumitrescu L, Gottesman O, Haessler JW, Haiman C,
Heiss G, Hsiung CA, Hung Y-J, Hwu C-M, Juang J-MJ, Le Marchand L, Lee I-T,
Lee W-J, Lin L-A, Lin D, Lin S-Y, Mackey RH, Martin LW, Pasaniuc B, Peters U,
Predazzi I, Quertermous T, Reiner AP, Robinson J, Rotter JI, Ryckman KK,
Schreiner PJ, Stahl E, Tao R, Tsai MY, Waite LL, Wang T-D, Buyske S, Chen Y-DI,
Cheng I, et al. Fine-mapping of lipid regions in global populations discovers
ethnic-specific signals and refines previously identified lipid loci. Hum Mol
Genet. 2016;25:5500–12.
16. Sorlie PD, Aviles-Santa LM, Wassertheil-Smoller S, Kaplan RC, Daviglus ML,
Giachello AL, Schneiderman N, Raij L, Talavera G, Allison M, LaVange L,
Chambless LE, Heiss G. Design and implementation of the Hispanic
community health study/study of Latinos. Ann Epidemiol. 2010;20:629–41.
17. LaVange, L. M., W. D. Kalsbeek, P. D. Sorlie, L. M. Avil??s-Santa, R. C. Kaplan, J.
Barnhart, K. Liu, A. Giachello, D. J. Lee, J. Ryan, M. H. Criqui, and J. P. Elder.
2010. Sample design and cohort selection in the Hispanic community
health study/study of Latinos. Ann Epidemiol 20: 642–649.
18. Conomos MP, Laurie CA, Stilp AM, Gogarten SM, McHugh CP, Nelson SC,
Sofer T, Fernández-Rhodes L, Justice AE, Graff M, Young KL, Seyerle AA,
Avery CL, Taylor KD, Rotter JI, Talavera GA, Daviglus ML, Wassertheil-Smoller
S, Schneiderman N, Heiss G, Kaplan RC, Franceschini N, Reiner AP, Shaffer JR,
Barr RG, Kerr KF, Browning SR, Browning BL, Weir BS, Avilés-Santa ML,
Papanicolaou GJ, Lumley T, Szpiro AA, North KE, Rice K, Thornton TA, Laurie
CC. Genetic diversity and association studies in US Hispanic/Latino
populations: applications in the Hispanic community health study/study of
Latinos. Am J Hum Genet. 2016;98:165–84.
19. Daviglus ML, Talavera GAG, Avilés-Santa ML, Allison M, Cai J, Criqui MH,
Gellman M, Giachello AL, Gouskova N, Kaplan RC, LaVange L, Penedo F,
Perreira K, Pirzada A, Schneiderman N, Wassertheil-Sctors and cardiovascular
diseases among Hispanic/Latino individuals of diverse bmoller S, Sorlie PD,
Graff et al. Lipids in Health and Disease  (2017) 16:200 Page 11 of 12
Stamler J. Prevalence of major cardiovascular risk faackgrounds in the
United States. JAMA. 2012;308:1775–84.
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of
low-density lipoprotein cholesterol in plasma, without use of the
preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
21. Wu J, Province MA, Coon H, Hunt SC, Eckfeldt JH, Arnett DK, Heiss G, Lewis
CE, Ellison RC, Rao DC, Rice T, Kraja AT. An investigation of the effects of
lipid-lowering medications: genome-wide linkage analysis of lipids in the
HyperGEN study. BMC Genet. 2007;8:60.
22. Sweeney ME, Johnson RR. Ezetimibe: an update on the mechanism of
action, pharmacokinetics and recent clinical trials. Expert Opin Drug Metab
Toxicol. 2007;3:441–50.
23. Design of the Women’s Health Initiative clinical trial and observational study.
The Women’s health initiative study group. Control Clin Trials. 1998;19:61–109.
24. Lorenzo C, Wagenknecht LE, D’Agostino RB, Rewers MJ, Karter AJ, Haffner
SM. Insulin resistance, beta-cell dysfunction, and conversion to type 2
diabetes in a multiethnic population: the insulin resistance atherosclerosis
study. Diabetes Care. 2010;33:67–72.
25. Henkin L, Bergman R, Bowden D, Ellsworth D, Haffner S, Langefeld C,
Mitchell B, Norris J, Rewers M, Saad M, Stamm E, Wagenknecht L, Rich S.
Genetic epidemiology of insulin resistance and visceral adiposity the IRAS
family study design and methods. Ann Epidemiol. 2003;13:211–7.
26. Xiang, A., S. Azen, L. Raffel, S. Tan, L. Cheng, T. Diaz, J, E. Toscano, P.
Henderson, H. Hodis, W. Hsueh, R. JI, and B. TA. 2001. Evidence for joint
genetic control of insulin sensitivity and systolic blood pressure in Hispanic
families with a hypertensive proband. Circulation 103: 78083.
27. Goodarzi MO, Guo X, Taylor KD, Quiñones MJ, Samayoa C, Yang H, Saad MF,
Palotie A, Krauss RM, Hsueh WA, Rotter JI. Determination and use of
haplotypes: ethnic comparison and association of the lipoprotein lipase
gene and coronary artery disease in Mexican-Americans. Genet Med. 2003;5:
322–7.
28. Hill C, Gerardo D, James F, Tyroler HA, Chambless LE, Romm J, Disanto AR,
Barr K, Bergsten J, Conrad J, Elliott R, Furr D, Hafer B, Haire A, Jensen J,
Johnson P, Marlow J, Monger B, Mooney D, Posey D, Sofley C, Tatum C,
Toledo A, Langford H, Asken B, Blackburn F, Bowman C, Feild L, Franklin R,
Hathorn D, Howell R, Nelson M, Overman V, Oxner S, Pitts D, Shelton G,
Edlavitch S, Cram K, Reed L, Murton G, Nabulsi A, Bowers M, Kuehl B,
Hamele H, Christman C, Costa D, Har S, Markam T, Neuing J. The
atherosclerosis risk in communities (ARIC) study: design and objectives. The
ARIC investigators. Am J Epidemiol. 1989;129:687–702.
29. Sofer T, Shaffer JR, Graff M, Qi Q, Stilp AM, Gogarten SM, North KE, Isasi CR,
Laurie CC, Szpiro AA. Meta-analysis of genome-wide association studies
with correlated individuals: application to the Hispanic community health
study/study of Latinos (HCHS/SOL). Genet Epidemiol. 2016;40:492–501.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Graff et al. Lipids in Health and Disease  (2017) 16:200 Page 12 of 12
